Preventive effect of itraconazole oral solution for invasive fungal infection in neutropenic patients with acute leukemia after chemotherapy
10.3760/cma.j.issn.1674-2397.2012.03.009
- VernacularTitle:伊曲康唑口服液对急性白血病化疗后粒细胞缺乏期侵袭性真菌感染的预防作用
- Author:
Wenbing DUAN
;
Yu ZHANG
;
Yongqiang WEI
;
Fen HUANG
;
Xiaolei WEI
;
Qi WEI
;
Xiaofang LI
;
Min DAI
;
Ru FENG
- Publication Type:Journal Article
- Keywords:
Leukemia;
Agranulocytosis;
Invasive fungal infection;
Itraconazole;
Prevention
- From:
Chinese Journal of Clinical Infectious Diseases
2012;05(3):162-164,183
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy of itraconazole oral solution for prevention of invasive fungal infection ( IFI ) in neutropenic patients with acute leukemia after chemotherapy.Methods Clinical data of 136 neutropenic patients with acute leukemia after chemotherapy at the Department of Hematology,Nanfang Hospital from January 2008 to December 2010 were retrospectively analyzed.Patients were divided into itraconazole group ( n =67 ) and control group ( n =69).There were 36 patients with acute nonlymphocytic leukemia ( ANLL),31 with acute lymphoblastic leukemia (ALL) in itraconazole group;while in control group,there were 30 patients with ANLL,38 with ALL and 1 with biphenotypic acute leukaemia (BAL).Patients in itraconazole group received intraconazole after chemotherapy until the neutrophil count was increased to 0.5 × 109/L or the body temperature returned to normal and without any imaging evidence of IFI.The incidence of IFI and clinical features were compared between the groups using SPSS 13.0 software.Pearson x2 test was used for nominal variables,for measurement data,t (normal distribution) or Mann-Whitney U (skewed distribution) test were used.Results There were 12 cases ( 17.9％ ) suffering from IFI in itraconazole group and 32 cases (46.4％) in the control group (x2 =12.59,P ＜ 0.01 ).For ANLL patients,the incidence of IFI in itraconazole group was significantly lower than that in control group ( 16.7％ vs.56.7％,x2 =11.53,P ＜0.01 ).In itraconazole group,the incidence of IFI in female patients was significantly lower than that in male patients ( 8.6％ vs.28.1％,x2 =4.35,P ＜0.05 ).And for the female patients,the incidence of IFI in itraconazole group was significantly lower than thatin the control group (8.6％ vs.44.7％,x2 =11.98,P＜0.01).Conclusion Itranconzole oral solution can effectively prevent IFI in neutropenic patients with acute leukemia after chemotherapy,especially for the female patients with ANLL.
